Artificial intelligence (AI) is opening new frontiers in the fight against idiopathic pulmonary fibrosis (IPF).

In a study published in Aging on Aug. 8, 2025, researchers at Insilico Medicine unveiled AI-powered models that uncover shared biological pathways between IPF and the aging process, pointing to novel opportunities for drug discovery, biomarker development and personalized treatment strategies for patients with the deadly lung disease.

“It is totally appropriate to treat IPF as its own disease and target the fibrotic processes that can happen only in the lung,” Carol Ann Satler, M.D., senior vice president of clinical development for the company and leader of the program, told Managed Healthcare Executive . “But we think that such a strategy needlessly narrows down the r

See Full Page